Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data sho ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...

Pharmaceuticals giant Merck & Company (MRK) has cut its full-year profit forecasts fearing a $200 million hit from President ...

Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

Germany's Merck KGaA is nearing a roughly $3.5 billion deal for SpringWorks Therapeutics , the Wall Street Journal reported ...

Reports Q1 revenue $15.5B, consensus $15.33B. “Our company made strong progress to start the year, with increasing contributions from our newer ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

Merck cut its 2025 adjusted earnings projection to a range between $8.82 and $8.97 a share from a previous estimate of $8.88 to $9.03 a share. The new guidance includes a charge of roughly $200 ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...